New research reveals that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional lifestyle programs.
Findings released in a major medical journal shows that while obese people can lose substantial amounts of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Individuals buying such treatments should be informed of the danger of rapid weight regain when the medication concludes," stated expert Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass within about a year and a half.
Weighing Approaches
The study, which examined 37 of studies involving over 9,000 of participants, compared the outcomes of these new drugs with conventional dieting.
The team emphasize that individuals who lose weight through diet and exercise typically see a more gradual weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Quick Regain
Nutrition scientists propose the way of the jabs explains the amplified rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Issue?
Health authorities advise the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the high risk of weight regain, the therapy might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who state that the findings "highlight the persistent character of excess weight," comparing it to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the medication report a powerful return of cravings.
"It felt as if a trigger that goes on and you're instantly extremely hungry," said an individual.
This challenge is worsened if patients have not developed permanent dietary or behavioural modifications during therapy.
Significant Interest
Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while these medications are effective agents for shedding pounds, they are not a magic cure and maintained weight loss hinges on combined lifestyle changes.
